Medical Research
Scleroderma Research Foundation
SAN FRANCISCO, CA
Total revenue
$12.2M
Total expenses
$9.6M
Net assets
$14.1M
Grants received
$6.0M
196 grants
EIN
680087234
Tax year
2024
Mission
The SRF is laser-focused on finding a cure for scleroderma by raising critical funds for research investments, fostering collaboration among the worlds top scientists and institutions to drive innovation, and raising awareness about this rare disease.
Programs
3 programs
The mission of the Scleroderma Research Foundation (SRF) is to find, fund, and facilitate the most promising, highest-quality research to cure scleroderma. We recruit the best and the brightest researchers to understand the causes, discover treatments, and ultimately eradicate this disease . At the SRF, research is at the center of all we do. Our Research Program is governed by the Board of Directors and supported by a volunteer Scientific Advisory Board comprised of some of the world's most highly regarded scientists who are leaders in their field of expertise. The Board of Directors and Scientific Advisors meet annually with researchers and clinicians from laboratories across the nation to select and fund the most promising scleroderma studies aimed at developing improved therapies to help patients live longer, fuller lives - and, ultimately, to find a cure for scleroderma.
SRF Education & Awareness Program: Many patients hear the word scleroderma for the first time when they are diagnosed. We strive to raise awareness and provide educational resources because lack of awareness about scleroderma often causes delays in treatment or misdiagnosis. As an innovator in scleroderma research, the SRF is uniquely qualified to provide those living with this disease, the medical community, and the general public with the most up-to-date, trusted and relevant news and information about complications, treatments, and related research through our website, webinars, annual patient forum, and monthly eNewsletter. And we deliver stories of impact that connect and inspire patients, as well as address issues related to diversity, equity, and inclusion that patients may encounter as they navigate diagnosis, treatment, and living with the disease.
The SRF Research Program: Led by a Scientific Advisory Board comprised of some of the most highly regarded scientists in the nation, the SRFs research program actively seeks out and recruits experts from the fields of rheumatology, immunology, genetics, and fibrosis, as well as, experts in cutting-edge technologies to join the scleroderma research community. With an intense focus on identifying projects and investigators likely to move scleroderma research forward, the SRF funds a diverse portfolio of projects led by top-tier investigators.
Financials
FY 2024
Revenue
Expenses
People
15 listed
Joanne Gold
Executive Dir.
$216K
40 hrs/wk
Luke Evnin PhD
Chairman
—
30 hrs/wk
Susan Feniger
Secretary
—
10 hrs/wk
Deann Wright
Treasurer
—
10 hrs/wk
Omar Baker MD
Board Member
—
2 hrs/wk
Sharon Dobie MD
Board Member
—
2 hrs/wk
Eric Kau MD
Board Member
—
2 hrs/wk
David Knoller
Board Member
—
1 hrs/wk
Violetta Merin
Board Member
—
2 hrs/wk
Regina Hall
Board Member
—
2 hrs/wk
Jeff Seaman
Board Member
—
2 hrs/wk
Gregory Gordon
Chief Medical Officer
$416K
40 hrs/wk
Gloria Blecha
VP Communications
$172K
40 hrs/wk
Kate Ceredona
Dir. Philanthropy
$152K
40 hrs/wk
Hannah Young
Dir. Communication
$130K
40 hrs/wk
Independent contractors
Kelly Oliver
CONQUEST consultant
Lauretta Sue Fredrick
CONQUEST consultant
Rondaxe Pharmaceuticals
CONQUEST consultant
Latham & Watkins LLP
CONQUEST consultant
Pharma e Market
CONQUEST consultant
Grants received
Showing 196 of 196
Funded by
$6.0M from 75 funders · 196 grants · 2017–2024
$1.5M · 7 grants · 2018–2023
$1.0M · 3 grants · 2020–2023
$858K · 3 grants · 2022–2024
$661K · 7 grants · 2017–2023
$297K · 7 grants · 2017–2023
$228K · 3 grants · 2022–2024
$195K · 6 grants · 2019–2024
$165K · 5 grants · 2020–2024